Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III trial to Evaluate the Efficacy of NBI-921352 (formerly XEN901) in SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE) Pediatric Patients

Next Previous
Trial Profile

A Phase II/III trial to Evaluate the Efficacy of NBI-921352 (formerly XEN901) in SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE) Pediatric Patients

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 12 Feb 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NBI 921352 (Primary)
  • Indications Encephalopathy; Epilepsy
  • Focus Therapeutic Use
  • Sponsors Xenon Pharmaceuticals

    • Most Recent Events

    • 04 Feb 2021 According to a Neurocrine Biosciences media release, based on feedback received in January 2021, the company plans to initiate this Phase II clinical study in adolescent patients (aged 12 years and older) with SCN8A-DEE in the third quarter of 2021, and the study protocol will be amended to include younger pediatric patients (aged 2-11 years) with SCN8A-DEE as soon as the FDA has reviewed and approved additional non-clinical information.
    • 08 Oct 2020 According to a Neurocrine Biosciences, Xenon Pharmaceuticals media release, the companies will engage with the FDA to address the feedback received with the goal of initiating this trial in 2021.
    • 08 Oct 2020 According to a Neurocrine Biosciences, Xenon Pharmaceuticals media release, the U.S. Food and Drug Administration(FDA) provided feedback on an Investigational New Drug (IND) application submitted to support this Phase II trial in pediatric SCN8A-DEE patients. As part of its review of the IND, the FDA is requesting additional non-clinical data to support dose justification in this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top